A P Pharma appoints CEO
This article was originally published in Scrip
AP Pharma (US) has appointed Ronald Prentki president, CEO and a member of its board, succeeding Gregory Turnbull, who will remain a company director and interim chief financial officer. Mr Prentki joins from the consultancy Easton Healthcare Ventures; before that he was president of Progenics Pharmaceuticals and vice-president of business development at the US division of Roche. AP Pharma is developing products based on its polymer-based drug delivery systems.